🇭🇰 港交所SIMCERE PHARMAQwen · 实盘不做把握 6/10不做原因:已被定价
北京时间·🕒 发布 21:26:00时区推断·⟳ 抓取 21:29:42·⚡ 决策 09-03 21:34:27 +4m45s·53.9 天前
先声药业RSV单抗英沐乐获NMPA批准上市，用于新生儿预防呼吸道合胞病毒下呼吸道感染
NMPA批准是正面但预期内的事件：8月20日合作已披露、III期数据已公开、NDA已递交，批准只是时间确认而非新增不确定性消除；收入兑现要到下一个RSV流行季（2026年10月后），短期无业绩增量；尼塞韦单抗已上市构成竞争；市值302亿港元相对峰值销售潜力（估计10-30亿元）弹性有限；昨日已因罗氏授权事件大涨7.64%，情绪已部分释放
📄 原文SIMCERE PHARMA↗ 原文
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the con…
不做 先声药业（02096.HK）
NMPA批准属预期兑现而非新增信息（合作8月20日已披露、III期数据已公开、NDA已递交）；收入兑现需等到2026年10月后下一个RSV流行季，短期无业绩增量；尼塞韦单抗已上市构成先发竞争；302亿港元市值下峰值销售弹性有限（~3-7%）；昨日罗氏授权已推动+7.64%部分消耗情绪窗口。综合增量信息不足、兑现周期长、竞争约束，无正期望edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
先声药业英沐乐获NMPA批准是正面事件，但属于预期兑现而非新增信息：合作权益8月20日已公告，III期数据早已公开，NDA递交后批准只是时间问题。收入兑现需等到2026年10月后的RSV流行季，短期无业绩贡献。尼塞韦单抗（赛诺菲/阿斯利康）已在中国上市，英沐乐面临竞争。以302亿港元市值计算，即使峰值销售达20亿元（乐观估计），对市值弹性约7%，且兑现周期长。昨日因罗氏SIM0660授权已涨7.64%，情绪窗口部分消耗。综合判断增量信息不足以支撑正期望交易。
🔎 新鲜度:最早出现 2026-09-03 · 扩散 low · price-in 风险 medium ↗
关键理由
- NMPA批准确认英沐乐可商业化，大中华区独家权益，峰值销售潜力10-30亿元
- RSV是婴幼儿住院首因，中国年新生儿约900万，被动免疫单抗有明确临床需求
- 先声5000人销售团队和抗感染领域商业化能力可支撑放量
主要风险
- 尼塞韦单抗（乐唯初）已在中国获批上市，英沐乐面临先发竞争和医保准入压力
- 收入兑现需等到2026年10月后下一个RSV流行季，短期无业绩贡献，催化时效长
反向证据
- 做多前查反向 · 来源 kb_search · 影响 weakens
未发现针对英沐乐的直接利空，但尼塞韦单抗先发优势和医保谈判压力构成竞争约束
检索:先声药业 英沐乐 利空 竞争 尼塞韦单抗 市场份额
先例如何影响了这次决策
对本次决策的影响:先例不足不改变AVOID结论，因核心判断基于增量信息不足和收入远期兑现
方向:无法从先例校准，但基于事件性质（预期内批准、远期待现收入）判断正面反应有限
涨幅量级:无高相似先例可用
工具执行结果 · 成功 7 · 降级 3 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 944 ms
{"result": "search_processed_events:agent query=`2096 rsv 单抗 批准 | simcere culevibart rsv approval | 先声药业 库莱韦拜单抗 上市 | 先声药业 英沐乐 nmpa 获批`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、7335 条本臂决策(完整)，返回 1 条候选。\n• 09-02 17:31 UTC(CST 09-03 01:31) [ticker] 不做 01801.HK,02096.HK,RHHBY.US (twitter) — Roche licenses a - stock_quote 成功 stock_tools HTTP · 1,381 ms
{ - fetch_decision_experience 成功 stock_tools HTTP · 879 ms
{ - kb_search 降级 stock_tools HTTP · 9,082 ms
{ - kb_fetch_document 成功 stock_tools HTTP · 154 ms
{ - kb_search 成功 stock_tools HTTP · 2,315 ms
{ - kb_search 成功 stock_tools HTTP · 7,654 ms
{ - search_case_library 成功 stock_tools HTTP · 291 ms
{"result": "search_case_library「02096.HK」—— 与这些标的相关的自家决策案例(本页 6 条,该标的全历史相关记录共 6 条；ENTER 只按该标的自己的腿统计):\n◆ 02096.HK：相关历史决策 6 条 · 其中该标的 ENTER 1 条(16.7%) · 已结算 1 笔 · 胜率 0% · 中位 -4.54% · 均值 -4.54% ⚠️只有 1 笔,样本太薄,只能当线索不能当规律\n↑ 胜率/收益口径:ENTER 当日之后 T+1 开盘入场、次日开盘出场,做空腿已按方向取反(所以正数=这个方向做对了)。统计的只有★那只票自己的腿。\n【对所查标 - kb_search 降级 stock_tools HTTP · 5,359 ms
{ - kb_search 降级 stock_tools HTTP · 9,034 ms
{
原文全文
展开原文 · 6,593 字
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited
take no responsibility for the contents of this announcement, make no representation as to its
accuracy or completeness and expressly disclaim any liability whatsoever for any loss
howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.
Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)
VOLUNTARY ANNOUNCEMENT
APPROVAL FOR MARKETING OF YINGMULE ® IN CHINA
BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
This announcement is made by Simcere Pharmaceutical Group Limited (the “Company”,
together with its subsidiaries, the “Group”) on a voluntary basis to inform shareholders and
potential investors of the Company about the latest business development of the Group.
The board (the “Board”) of directors (the “Directors”) of the Company is pleased to
announce that, on September 3, 2026, the domestic Class 1 biological innovative drug
Culevibart Injection (trade name: Yingmule ®), developed under the strategic cooperation
between the Group and Reyoung (Shandong) Biopharmaceutical Co., Ltd. (“Reyoung Bio”)
was approved for marketing in China by the National Medical Products Administration
(NMPA) of China. It is indicated for newborns and infants born at or after 35 weeks of
gestational age who are entering or born during their first respiratory syncytial virus (“RSV”)
epidemic season, to prevent lower respiratory tract infections caused by RSV, excluding
children with chronic lung disease CLD, including bronchopulmonary dysplasia (BPD) or
clinically significant congenital respiratory abnormalities. On August 20, 2026, the Group
entered into a strategic cooperation with Reyoung Bio, obtaining the exclusive
commercialization rights of Yingmule ® in Greater China.
–1–
ABOUT CULEVIBART
Culevibart is a recombinant human IgG1κ monoclonal antibody, which primarily provides
passive immunity by targeting epitope II of the respiratory syncytial virus F protein.
Culevibart achieves half-life extension of the antibody through Fc segment engineering,
providing newborns and infants with continuous protection covering the entire RSV epidemic
season via a single intramuscular injection. As a passive immunization agent, Culevibart can
rapidly reach protective antibody levels upon administration to quickly establish a protective
barrier, making it suitable for the broad infant and toddler population currently lacking active
immunization options.
The pivotal Phase III study supporting this approval is a multicenter, randomized,
double-blind, placebo-controlled clinical study. Trial data showed that at 150 days post-dose,
compared with placebo, the efficacy of Culevibart against RSV-caused lower respiratory tract
infections requiring medical intervention (outpatient, emergency or hospitalization) was
85.32%, and the efficacy against RSV infection-induced hospitalization was 83.27%. At 240
days post-dose, compared with placebo, the efficacy of Culevibart against RSV-caused lower
respiratory tract infections requiring medical intervention (outpatient, emergency or
hospitalization) caused by RSV was 82.04%, and the efficacy against RSV infection-induced
hospitalization was 78.44%. In addition, a Phase IIIb study targeting infants and toddlers
aged 1 to 2 years is ongoing to further expand the applicable age range.
ABOUT REYOUNG BIO
Reyoung (Shandong) Biopharmaceutical Co., Ltd. specializes in the R&D and
commercialization of antibody-based biologic drugs, with a core focus on passive
immunization for prophylaxis and treatment of infectious diseases, alongside exploratory
programs in tumor immunotherapy. Reyoung Bio utilizes proprietary technology platforms
and the identification and screening of rare elite samples to discover and develop
first-in-class antibody drugs characterized by high specificity, high affinity, and
broad-spectrum activity. Reyoung Bio is committed to delivering differentiated and
innovative solutions for major diseases.
–2–
ABOUT THE GROUP
The Company is an innovation and R&D-driven pharmaceutical company. The Group focuses
on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with
forward-looking layout of disease areas that may have significant clinical needs in the future,
aiming to achieve the mission of “for patients, for life”. Driven by its in-house R&D efforts
and synergistic innovation, the Company has established strategic cooperation partnerships
with many innovative companies and research institutes.
By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer
Hong Kong, September 3, 2026
As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman
and executive Director; Mr. WAN Yushan and Ms. WANG Xi as the executive Directors;
Mr. TANG Renhong as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo,
Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.
–3–
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負
責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部
或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。
Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
（於 香 港 註 冊 成 立 的 有 限 公 司）
（股 份 代 號 ：2096）
自願公告
英沐樂 ®獲國家藥品監督管理局批准在中國上市
本公告由先聲藥業集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）自
願作出，以告知本公司股東及潛在投資者本集團最新業務更新。
本公司董事（「董事」）會（「董事會」）欣然宣佈，於2026年9月3日，本集團與瑞陽
（山東）生物製藥有限公司（「瑞陽生物」）戰略合作的國產1類生物新藥庫萊韋拜單
抗注射液（商品名：英沐樂 ® ）獲中國國家藥品監督管理局（NMPA）批准在中國上
市，用於即將進入或出生在第一個呼吸道合胞病毒（「RSV」）流行季的胎齡≥35周
的新生兒和嬰兒，預防RSV引起的下呼吸道感染，不包括患有慢性肺疾病CLD，
包含支氣管肺發育異常（BPD）或伴有臨床意義的先天性呼吸道異常的兒童。2026
年8月20日，本集團與瑞陽生物達成戰略合作，獲得英沐樂 ® 在大中華區的獨家商
業化權益。
–1–
關於庫萊韋拜單抗
庫萊韋拜單抗是一種重組人源IgG1κ單克隆抗體，主要通過靶向呼吸道合胞病毒F
蛋白Ⅱ號表位提供被動免疫。庫萊韋拜單抗經過Fc段改造實現抗體半衰期延長，
通過單次肌肉注射，為新生兒和嬰兒提供覆蓋整個RSV流行季的持續保護。作為
被動免疫制劑，庫萊韋拜單抗給藥後可迅速達到保護性抗體水平，快速建立保護
屏障，適用於尚無主動免疫手段可用的廣大嬰幼兒群體。
支撐本次獲批的關鍵性III期研究是一項多中心、隨機、雙盲、安慰劑對照的臨床
研究，試驗數據顯示在給藥後150天，與安慰劑相比，庫萊韋拜單抗對RSV引起的
需醫學干預（門急診或住院）的下呼吸道感染的保護效力為85.32%，對RSV感染引
起住院的保護效力為83.27%；給藥後240天，與安慰劑相比，庫萊韋拜單抗對RSV
引起的需醫學干預（門急診或住院）的下呼吸道感染的保護效力為82.04%，對RSV
感染引起住院的保護效力為78.44%。此外，一項針對1-2歲嬰幼兒的IIIb期研究正
在進行中，以進一步拓展適用年齡。
關於瑞陽生物
瑞陽（山東）生物製藥有限公司主要從事抗體類生物大分子藥物的研發及產業化，
重點聚焦感染性疾病領域的被動免疫預防與治療，同時佈局腫瘤免疫等創新方
向。瑞陽生物依託自主技術平台，並結合對稀有精英樣本的鑒定與篩選，致力於
發現和開發具有高特異性、高親和力及廣譜活性的源頭創新抗體藥物，為重大疾
病提供具有差異化價值的創新解決方案。
–2–
關於本集團
本公司是一家創新與研發驅動的製藥公司。本集團聚焦神經科學、抗腫瘤、自身
免疫及抗感染領域，同時積極前瞻性佈局未來有重大臨床需求的疾病領域，履行
「為患者而生」的企業使命。本公司以自主研發及協同創新雙輪驅動，與多家創新
型企業、科研院校建立戰略合作夥伴關係。
承董事會命
先聲藥業集團有限公司
董事長兼首席執行官
任晉生先生
香港，2026年9月3日
於本公告日期，董事會包括董事長兼執行董事任晉生先生；執行董事萬玉山先生
及王熙女士；非執行董事唐任宏先生；獨立非執行董事宋瑞霖先生、汪建國先
生、王新華先生及宋嘉桓先生。
–3–
take no responsibility for the contents of this announcement, make no representation as to its
accuracy or completeness and expressly disclaim any liability whatsoever for any loss
howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.
Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)
VOLUNTARY ANNOUNCEMENT
APPROVAL FOR MARKETING OF YINGMULE ® IN CHINA
BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
This announcement is made by Simcere Pharmaceutical Group Limited (the “Company”,
together with its subsidiaries, the “Group”) on a voluntary basis to inform shareholders and
potential investors of the Company about the latest business development of the Group.
The board (the “Board”) of directors (the “Directors”) of the Company is pleased to
announce that, on September 3, 2026, the domestic Class 1 biological innovative drug
Culevibart Injection (trade name: Yingmule ®), developed under the strategic cooperation
between the Group and Reyoung (Shandong) Biopharmaceutical Co., Ltd. (“Reyoung Bio”)
was approved for marketing in China by the National Medical Products Administration
(NMPA) of China. It is indicated for newborns and infants born at or after 35 weeks of
gestational age who are entering or born during their first respiratory syncytial virus (“RSV”)
epidemic season, to prevent lower respiratory tract infections caused by RSV, excluding
children with chronic lung disease CLD, including bronchopulmonary dysplasia (BPD) or
clinically significant congenital respiratory abnormalities. On August 20, 2026, the Group
entered into a strategic cooperation with Reyoung Bio, obtaining the exclusive
commercialization rights of Yingmule ® in Greater China.
–1–
ABOUT CULEVIBART
Culevibart is a recombinant human IgG1κ monoclonal antibody, which primarily provides
passive immunity by targeting epitope II of the respiratory syncytial virus F protein.
Culevibart achieves half-life extension of the antibody through Fc segment engineering,
providing newborns and infants with continuous protection covering the entire RSV epidemic
season via a single intramuscular injection. As a passive immunization agent, Culevibart can
rapidly reach protective antibody levels upon administration to quickly establish a protective
barrier, making it suitable for the broad infant and toddler population currently lacking active
immunization options.
The pivotal Phase III study supporting this approval is a multicenter, randomized,
double-blind, placebo-controlled clinical study. Trial data showed that at 150 days post-dose,
compared with placebo, the efficacy of Culevibart against RSV-caused lower respiratory tract
infections requiring medical intervention (outpatient, emergency or hospitalization) was
85.32%, and the efficacy against RSV infection-induced hospitalization was 83.27%. At 240
days post-dose, compared with placebo, the efficacy of Culevibart against RSV-caused lower
respiratory tract infections requiring medical intervention (outpatient, emergency or
hospitalization) caused by RSV was 82.04%, and the efficacy against RSV infection-induced
hospitalization was 78.44%. In addition, a Phase IIIb study targeting infants and toddlers
aged 1 to 2 years is ongoing to further expand the applicable age range.
ABOUT REYOUNG BIO
Reyoung (Shandong) Biopharmaceutical Co., Ltd. specializes in the R&D and
commercialization of antibody-based biologic drugs, with a core focus on passive
immunization for prophylaxis and treatment of infectious diseases, alongside exploratory
programs in tumor immunotherapy. Reyoung Bio utilizes proprietary technology platforms
and the identification and screening of rare elite samples to discover and develop
first-in-class antibody drugs characterized by high specificity, high affinity, and
broad-spectrum activity. Reyoung Bio is committed to delivering differentiated and
innovative solutions for major diseases.
–2–
ABOUT THE GROUP
The Company is an innovation and R&D-driven pharmaceutical company. The Group focuses
on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with
forward-looking layout of disease areas that may have significant clinical needs in the future,
aiming to achieve the mission of “for patients, for life”. Driven by its in-house R&D efforts
and synergistic innovation, the Company has established strategic cooperation partnerships
with many innovative companies and research institutes.
By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer
Hong Kong, September 3, 2026
As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman
and executive Director; Mr. WAN Yushan and Ms. WANG Xi as the executive Directors;
Mr. TANG Renhong as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo,
Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.
–3–
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負
責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部
或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。
Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
（於 香 港 註 冊 成 立 的 有 限 公 司）
（股 份 代 號 ：2096）
自願公告
英沐樂 ®獲國家藥品監督管理局批准在中國上市
本公告由先聲藥業集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）自
願作出，以告知本公司股東及潛在投資者本集團最新業務更新。
本公司董事（「董事」）會（「董事會」）欣然宣佈，於2026年9月3日，本集團與瑞陽
（山東）生物製藥有限公司（「瑞陽生物」）戰略合作的國產1類生物新藥庫萊韋拜單
抗注射液（商品名：英沐樂 ® ）獲中國國家藥品監督管理局（NMPA）批准在中國上
市，用於即將進入或出生在第一個呼吸道合胞病毒（「RSV」）流行季的胎齡≥35周
的新生兒和嬰兒，預防RSV引起的下呼吸道感染，不包括患有慢性肺疾病CLD，
包含支氣管肺發育異常（BPD）或伴有臨床意義的先天性呼吸道異常的兒童。2026
年8月20日，本集團與瑞陽生物達成戰略合作，獲得英沐樂 ® 在大中華區的獨家商
業化權益。
–1–
關於庫萊韋拜單抗
庫萊韋拜單抗是一種重組人源IgG1κ單克隆抗體，主要通過靶向呼吸道合胞病毒F
蛋白Ⅱ號表位提供被動免疫。庫萊韋拜單抗經過Fc段改造實現抗體半衰期延長，
通過單次肌肉注射，為新生兒和嬰兒提供覆蓋整個RSV流行季的持續保護。作為
被動免疫制劑，庫萊韋拜單抗給藥後可迅速達到保護性抗體水平，快速建立保護
屏障，適用於尚無主動免疫手段可用的廣大嬰幼兒群體。
支撐本次獲批的關鍵性III期研究是一項多中心、隨機、雙盲、安慰劑對照的臨床
研究，試驗數據顯示在給藥後150天，與安慰劑相比，庫萊韋拜單抗對RSV引起的
需醫學干預（門急診或住院）的下呼吸道感染的保護效力為85.32%，對RSV感染引
起住院的保護效力為83.27%；給藥後240天，與安慰劑相比，庫萊韋拜單抗對RSV
引起的需醫學干預（門急診或住院）的下呼吸道感染的保護效力為82.04%，對RSV
感染引起住院的保護效力為78.44%。此外，一項針對1-2歲嬰幼兒的IIIb期研究正
在進行中，以進一步拓展適用年齡。
關於瑞陽生物
瑞陽（山東）生物製藥有限公司主要從事抗體類生物大分子藥物的研發及產業化，
重點聚焦感染性疾病領域的被動免疫預防與治療，同時佈局腫瘤免疫等創新方
向。瑞陽生物依託自主技術平台，並結合對稀有精英樣本的鑒定與篩選，致力於
發現和開發具有高特異性、高親和力及廣譜活性的源頭創新抗體藥物，為重大疾
病提供具有差異化價值的創新解決方案。
–2–
關於本集團
本公司是一家創新與研發驅動的製藥公司。本集團聚焦神經科學、抗腫瘤、自身
免疫及抗感染領域，同時積極前瞻性佈局未來有重大臨床需求的疾病領域，履行
「為患者而生」的企業使命。本公司以自主研發及協同創新雙輪驅動，與多家創新
型企業、科研院校建立戰略合作夥伴關係。
承董事會命
先聲藥業集團有限公司
董事長兼首席執行官
任晉生先生
香港，2026年9月3日
於本公告日期，董事會包括董事長兼執行董事任晉生先生；執行董事萬玉山先生
及王熙女士；非執行董事唐任宏先生；獨立非執行董事宋瑞霖先生、汪建國先
生、王新華先生及宋嘉桓先生。
–3–
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。